Alkermes (ALKS) Stock Climbs +27.6% on Positive Alixorexton Data and Pipeline Momentum
Key Takeaways
- Alkermes shares surged approximately 27.6% over the past 30 days, climbing from $42.76 on June 3 to $54.57 as of July 2, 2026, driven by a series of positive clinical and regulatory catalysts for its lead orexin agonist, alixorexton.
- The stock has gained roughly 56% over the last quarter, reflecting mounting investor confidence in the company's expanding neuroscience pipeline and sleep-medicine franchise.
- Detailed Phase 2 Vibrance-2 data presented at the SLEEP 2026 conference demonstrated statistically significant improvements in wakefulness and reduced daytime sleepiness in narcolepsy type 2 patients, a population without known orexin deficiency.
- Orphan drug designations from both the U.S. FDA and European Commission, combined with the initiation of a global Phase 3 Brilliance program, have meaningfully de-risked the alixorexton development pathway.
- Multiple Wall Street analysts raised price targets, with TD Cowen lifting its target to $50, Needham to $54, and Jefferies maintaining a Buy rating with a $59 target.
Alkermes (ALKS) Company Overview and Market Position
Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in the field of neuroscience. Headquartered in Dublin, Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio, the company markets a portfolio of proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. Its commercial franchise includes Vivitrol, Aristada, Lybalvi, and the recently acquired LUMRYZ. Alkermes' pipeline is anchored by alixorexton, a novel oral selective orexin 2 receptor agonist in late-stage development for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, with additional early-stage programs targeting ADHD and fatigue associated with multiple sclerosis and Parkinson's disease. Investors follow the stock closely due to its dual identity as a profitable commercial-stage company and a high-upside pipeline story in the rapidly emerging orexin therapeutic class.
ALKS Stock Price Performance: Last 30 Days vs. Quarter
Alkermes shares have delivered a powerful rally over the past 30 days, advancing approximately 27.6% from a closing price of $42.76 on June 3, 2026, to $54.57 as of July 2, 2026. The move was not a single-day spike but rather a sustained upward grind punctuated by sharp accelerations around key news events, particularly the mid-June SLEEP 2026 conference and subsequent analyst target increases. Trading volume expanded significantly during the rally, with several sessions recording multiples of the average daily volume, indicating strong institutional participation. When I reviewed comparable names in the sector, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Zooming out to the quarterly view, the stock has climbed roughly 56% from the $34–$35 range in early April 2026. This broader advance reflects a fundamental re-rating of the company as the investment community has increasingly priced in the potential of the orexin pipeline. The quarterly trend has been characterized by higher lows and higher highs, with pullbacks proving shallow and short-lived, a hallmark of accumulation by institutional investors.
What Drove ALKS Stock Price in the Last 30 Days
The primary catalyst for the 30-day surge was the presentation of detailed positive results from the Vibrance-2 Phase 2 study of alixorexton in adults with narcolepsy type 2 at the SLEEP 2026 conference in Baltimore on June 17. The data showed that once-daily alixorexton met dual primary endpoints with statistically significant and clinically meaningful improvements in wakefulness, as measured by the Maintenance of Wakefulness Test, and reductions in excessive daytime sleepiness on the Epworth Sleepiness Scale. Notably, improvements in patient-reported fatigue and cognition were sustained through a 13-week open-label extension, and the drug was generally well tolerated with no serious treatment-emergent adverse events.
Just days before the conference, on June 15, Alkermes announced that alixorexton had received orphan drug designations from the U.S. FDA for idiopathic hypersomnia and from the European Commission for narcolepsy, providing potential market exclusivity and regulatory incentives. The company also confirmed that enrollment is underway for the global Phase 3 Brilliance program across narcolepsy type 1 and type 2. These regulatory milestones, combined with the robust Phase 2 data, triggered a wave of analyst upgrades. TD Cowen raised its price target to $50 from $42, Needham lifted its target to $54 from $50, and Jefferies reiterated a Buy rating with a $59 target. Additionally, at the Goldman Sachs Global Healthcare Conference on June 11, management outlined a broader orexin franchise vision extending beyond sleep disorders into ADHD and fatigue-related conditions, further fueling investor enthusiasm.
What Drove ALKS Stock Performance Over the Last Quarter
The quarterly rally was built on a foundation of steadily accumulating positive developments. In late March, Alkermes reported stronger-than-expected Q1 2026 results, with revenue surpassing consensus estimates driven by higher sales across Vivitrol, Aristada, Lybalvi, and the newly acquired LUMRYZ. The company reaffirmed full-year revenue guidance above $1.7 billion, providing a stable base-business backdrop against which the pipeline story could flourish.
The acquisition and integration of Avadel, which closed earlier in the year, brought LUMRYZ into the portfolio along with an experienced sleep-medicine commercial team, giving Alkermes established relationships with physicians, payers, and treatment centers ahead of a potential alixorexton launch. Throughout April and May, the stock grinded higher as investors digested the implications of the FDA's Breakthrough Therapy designation for alixorexton in narcolepsy type 1, granted in January 2026, and the initiation of the Phase 3 Brilliance studies. The planned CEO transition, with COO Blair Jackson set to take over from longtime CEO Richard Pops in August, was viewed by the market as a well-managed succession that preserves strategic continuity. The combination of commercial execution, strategic M&A integration, and pipeline advancement created a powerful narrative that drove sustained institutional buying throughout the quarter.
Trending AI Robots
For traders and investors seeking to complement their fundamental analysis with data-driven strategies, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of bots trading thousands of tickers across diverse strategies, timeframes, and performance profiles, but only the top-performing and most relevant bots are featured in this section. These bots employ technical analysis, pattern recognition, and algorithmic decision-making to identify opportunities in real time, providing a quantitative lens that can help traders navigate volatile market conditions. Whether you are looking for short-term swing trading signals or longer-term trend-following approaches, exploring the Trending AI Robots page can offer actionable insights to enhance your trading toolkit.
ALKS Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several key factors will shape Alkermes' stock trajectory. The most important near-term catalyst is the continued enrollment and eventual data readouts from the Phase 3 Brilliance program for alixorexton in narcolepsy type 1 and type 2. Any updates on enrollment pace, site activation, or regulatory interactions will be closely scrutinized. The Phase 2 Vibrance-3 study in idiopathic hypersomnia, expected to complete enrollment in the fourth quarter of 2026, represents another significant value-inflection point. On the commercial side, investors should monitor LUMRYZ revenue contributions, prescription trends for the legacy psychiatry portfolio, and any updates to full-year 2026 financial guidance. The planned CEO transition in August warrants attention, though the market currently views it as a non-disruptive event. Broader sector considerations include competitive developments in the orexin class, particularly from Takeda, and the evolving regulatory landscape for sleep-disorder therapies. Macroeconomic factors such as interest rate expectations and biotech sector fund flows may also influence sentiment, but the stock's primary driver remains execution on the alixorexton clinical program.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALKS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ALKS turned positive on June 22, 2026. Looking at past instances where ALKS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 213 cases where ALKS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ALKS moved out of overbought territory on July 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ALKS broke above its upper Bollinger Band on June 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.943) is normal, around the industry mean (46.452). P/E Ratio (57.722) is within average values for comparable stocks, (99.681). ALKS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.697). ALKS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (5.590) is also within normal values, averaging (114.852).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement